-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42

Benzinga·11/04/2026 18:05:48
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.